Opendata, web and dolomites


EVA - patient ventilation beyond limits

Total Cost €


EC-Contrib. €






 EVA project word cloud

Explore the words cloud of the EVA project. It provides you a very rough idea of what is the project "EVA" about.

outcome    reg    entered    assistance    prevent    market    injury    2016    ventilate    mechanically    expiration    sheer    distributors    demonstration    markets    sold    close    expiratory    surgical    q3    eva    disposable    care    countries    device    opinion    trials    instead    trl6    billion    executed    world    catheter    china    circulation    flagship    netherlands    protected    centers    ventrain    2011    clinical    ireland    tube    workshops    academic    reducing    usa    lung    marking    patient    registrations    medical    manual    patients    penetration    16    brand    form    patent    globally    russia    sessions    icu    meeting    training    2nd    conservative    families    ventinova    marketing    organizing    leaders    blood    400    careful    standard    innovative    ce    emergency    stress    ventilator    designed    manufactured    generation    first    full    ventilation    basic    invasive    negative    lungs    thick    500    thin    ensured    suction    elective    pressures    automated    launch   

Project "EVA" data sheet

The following table provides information about the project.


Organization address
postcode: 5652 BJ
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website
 Total cost 2˙397˙540 €
 EC max contribution 1˙890˙000 € (79%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2. (PRIORITY 'Industrial leadership')
 Code Call H2020-FTIPilot-2015-1
 Funding Scheme IA
 Starting year 2015
 Duration (year-month-day) from 2015-11-01   to  2018-10-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VENTINOVA MEDICAL BV NL (EINDHOVEN) coordinator 793˙261.00
3    UNITRON INNOTECH BV NL (HENGELO) participant 390˙999.00
4    REGION HOVEDSTADEN DK (HILLEROD) participant 63˙000.00


 Project objective

EVA - Expiratory Ventilation Assistance – , or expiration by suction, is an innovative method to mechanically ventilate patients and is a key step in ventilation towards less-invasive, tailored and improved patient care as it enables: 1. full ventilation through a thin catheter instead of a thick tube 2. low and – if needed – negative pressures in the lungs promoting blood circulation 3. controlling the expiration, reducing sheer stress, which may prevent lung injury and improve patient outcome.

The EVA technology has already been on the market for some years in its most basic form: the manual, disposable emergency ventilator Ventrain®. Since market launch in 2011, Ventrain® is now being sold by 16 distributors in over 20 countries. Ventinova’s flagship is the “EVA device”: a fully automated ventilator based on EVA technology meeting the emerging needs of less invasive, tailored and improved patient care. First is focused on the large markets of elective surgical procedures and emergency care (€ 400 M, globally) and in 2nd generation on ICU-ventilation (€ 500 M, globally), before becoming ‘standard care’ (€ 4.6 billion, globally). The device, currently at TRL6, is still in development and CE marking is expected in Q3 2016. Next to marketing activities, such as organizing workshops and training sessions, and careful selection and support of distributors, penetration of the conservative medical market should be ensured by demonstration of better and tailored patient care using EVA ventilation in pre-clinical studies and controlled clinical trials. These are to be designed and executed in close collaboration with Key Opinion Leaders of established and world leading academic medical centers.

The described technology and products are protected by 5 patent families and design and brand registrations. The products are manufactured in The Netherlands and a dedicated catheter in Ireland. After CE marking, large non-EU markets are to be entered (e.g. USA, China, Russia).


List of deliverables.
Reports of communication activities Documents, reports 2019-09-06 09:01:40
Evaluation of benefit personalised care Documents, reports 2019-09-06 09:01:40
Obtained FDA approval Websites, patent fillings, videos etc. 2019-09-06 09:01:40
Submission for publication Documents, reports 2019-09-06 09:01:40
Workshop organisation Websites, patent fillings, videos etc. 2019-09-06 09:01:40
Annual showcasing Websites, patent fillings, videos etc. 2019-09-06 09:01:40
Obtained CE marking Websites, patent fillings, videos etc. 2019-09-06 09:01:40
Evaluation of lung protective effects Documents, reports 2019-09-06 09:01:40
Evaluation of safe use in Pigs Documents, reports 2019-09-06 09:01:40

Take a look to the deliverables list in detail:  detailed list of EVA deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EVA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EVA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.)

Innovation Principle (2019)

Developing an Innovation-Friendly Legislative Culture – the Innovation Principle at Work

Read More  

PULSe (2017)

Pervasive Ubiquitous Lightwave SEnsor

Read More  

MedEye (2017)

Accelerated market launch of MedEye, a plug-and-play medication safety solution

Read More